Healthcare VC, Barcelona

Asabys Partners

Venture capital firm · Barcelona · Founded July 2020

Quick read

Asabys Partners is a Barcelona-based healthcare VC founded in July 2020. It backs healthtech and biopharma companies across Spain and Europe, with ambitions to build a beyond €1 billion life sciences platform by 2030. The firm runs multiple funds under the Sabadell Asabys Health Innovation Investments brand and recently absorbed Aliath Bioventures to expand its team and reach.

Key facts

Founded
July 2020
Employees
292
Sectors
healthcare, biotech
Website
asabys.com

Investment thesis

Asabys invests across healthtech and biopharma — from digital health to drug discovery — with a focus on Spain and Southern Europe, targeting companies pushing the scientific boundaries of human healthcare.

Recent activity

  • May 2026fundraise
    Asabys launched a new tech-transfer fund, Asabys Invierte Tech Transfer FCRE, targeting up to €120 million. The fund was anchored by a €74.5 million commitment from CDTI and the European Investment Fund (EIF) through the Innvierte Deep Start programme. It will invest exclusively in life-sciences spin-offs from universities and research centres, with the first spin-off targeted for creation in 2026. farodevigo.es
  • Mar 2026press
    Managing Partner Clara Campàs attended the Invest Europe Investors' Forum 2026 in Geneva on 18–19 March, representing Asabys at the LP-facing event. es.linkedin.com
  • Mar 2026press
    Operating Partner Emilio Erazo-Fischer represented Asabys at BIO-Europe Spring in Lisbon on 23–25 March 2026. es.linkedin.com
  • Mar 2026investment
    Asabys reinvested in Belgian portfolio company Augustine Therapeutics as part of a €78 million round that also included Novo Holdings and Jeito. tracxn.com
  • Nov 2025investment
    Qida raised €37 million in a round co-led by Asabys Partners and COFIDES (Social Impact Fund), with Quadrille Capital as lead investor. Qida provides digital home-care services for senior citizens in Spain. asabys.com
  • Nov 2025investment
    BStartup10 led an investment round in Miramoon Pharma alongside Asabys, Alta Life Sciences, and Columbus Venture Partners. tracxn.com
  • Oct 2025fundraise
    Asabys integrated Aliath Bioventures (formerly Alta Life Sciences) into its platform through a deal with AltamarCAM Partners. The consolidation pushed AUM from €300 million to over €400 million. Asabys will co-manage AltamarCAM's Alta Life Sciences Spain I FCR fund and targets €1 billion AUM by 2030. prnewswire.com
  • Apr 2025press
    Portfolio company Quibim announced a new Board of Directors to support growth and strategic expansion, with Asabys among the existing investor base. tracxn.com
  • Oct 2025fundraise
    Asabys Partners integrated Aliath Bioventures (formerly Alta Life Sciences) in a strategic consolidation backed by AltamarCAM Partners, lifting AUM from $351 million to over $468 million. The firm set a target of exceeding €1 billion AUM by 2030, with expansion plans covering tech transfer, company creation, scale-ups, and growth-stage deals. Both firms had previously co-invested in Deepull, Ona Therapeutics, and Inbrain Neuroelectronics. bioxconomy.com
  • 2026investment
    Asabys launched Oriva Therapeutics, a pre-seed women's health biotech it created by combining two clinical-stage assets from Oncostellae and Medibiofarma. The Sabadell Asabys II fund led the pre-seed round. Oriva's lead program, ORV-362, a non-hormonal therapy for endometriosis, entered Phase I in January 2026; a second program targeting uterine fibroids is expected in Phase I in Q1 2027. catalonia.health
  • 2026investment
    Asabys led the first closing of Augustine Therapeutics' Series A at €17 million, with co-investors Eli Lilly and the US-based Charcot-Marie-Tooth Research Foundation. The Belgian biotech focuses on treatments for neurodegenerative and cardiometabolic diseases. Clara Campàs joined Augustine's Board of Directors in connection with the round. cbinsights.com
  • 2026investment
    Nuage Therapeutics, a spin-off from IRB Barcelona and ICREA co-founded by researcher Xavier Salvatella, closed a financing round backed by Sabadell Asabys. The company targets drug discovery against therapeutic targets currently considered undruggable. startupsreal.com

Notable investments

Key people

Named individuals at the firm. We don't expose direct email or phone — use their LinkedIn for outreach.

  • Sylvain Sachot · Partner
  • Guillem Masferrer · Partner
  • Josep Lluis Sanfeliu · Founder & Managing Partner
  • Clara Campàs · Founding Partner

Sources

Other VCs in Spain

Explore VCs by sector

Globally

Frequently asked

What is Asabys Partners?+

Asabys Partners is a Barcelona-based healthcare VC founded in July 2020. It backs healthtech and biopharma companies across Spain and Europe, with ambitions to build a beyond €1 billion life sciences platform by 2030.

Where is Asabys Partners headquartered?+

Asabys Partners is headquartered in Barcelona, Spain.

When was Asabys Partners founded?+

Asabys Partners was founded in July 2020.

What sectors does Asabys Partners invest in?+

Asabys Partners focuses on healthcare, biotech. They primarily invest in these sectors.

How do I prepare for a meeting with Asabys Partners?+

Brief generates a structured pre-meeting briefing on any person at Asabys Partners — quick read, recent activity, points of view, and conversation openers tailored to what you sell. Sign in to get personalised openers for your product.

Meeting with someone at Asabys Partners?

Brief generates a structured pre-meeting briefing on any person in seconds.

Try Brief →

Generated by briefthecall.com from public web sources. Last updated August 9, 2026. Each claim is linked to its source above.

Automatically generated by AI from public sources. May be inaccurate or out of date. Remove or correct this profile →